PH26198A - Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon - Google Patents
Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon Download PDFInfo
- Publication number
- PH26198A PH26198A PH35292A PH35292A PH26198A PH 26198 A PH26198 A PH 26198A PH 35292 A PH35292 A PH 35292A PH 35292 A PH35292 A PH 35292A PH 26198 A PH26198 A PH 26198A
- Authority
- PH
- Philippines
- Prior art keywords
- interferon
- basal cell
- cell carcinoma
- treatment
- alpha
- Prior art date
Links
- 206010004146 Basal cell carcinoma Diseases 0.000 title claims abstract description 26
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 15
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims description 20
- 102000014150 Interferons Human genes 0.000 claims description 27
- 108010050904 Interferons Proteins 0.000 claims description 27
- 229940079322 interferon Drugs 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 11
- 108010078049 Interferon alpha-2 Proteins 0.000 abstract description 10
- 229960003507 interferon alfa-2b Drugs 0.000 abstract description 9
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 230000003902 lesion Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 4
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 102000051099 human IFNA2 Human genes 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000007387 excisional biopsy Methods 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000007386 incisional biopsy Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 102000051101 human IFNA1 Human genes 0.000 description 1
- 108700028467 human IFNA1 Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000000743 nodular basal cell carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000011138 superficial basal cell carcinoma Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86664486A | 1986-05-27 | 1986-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26198A true PH26198A (en) | 1992-03-18 |
Family
ID=25348060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH35292A PH26198A (en) | 1986-05-27 | 1987-05-25 | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0248583B1 (de) |
| JP (1) | JPS62289526A (de) |
| KR (1) | KR870010871A (de) |
| AT (1) | ATE100717T1 (de) |
| AU (1) | AU601741B2 (de) |
| CA (1) | CA1295243C (de) |
| DE (1) | DE3788899T2 (de) |
| DK (1) | DK264787A (de) |
| ES (1) | ES2061496T3 (de) |
| IE (1) | IE62318B1 (de) |
| IL (1) | IL82654A0 (de) |
| PH (1) | PH26198A (de) |
| ZA (1) | ZA873743B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
| EP0278715A3 (de) * | 1987-02-09 | 1989-03-08 | Schering Corporation | Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen |
| EP0446279A1 (de) * | 1988-12-01 | 1991-09-18 | Schering Corporation | Intralesionsbehandlung von schuppenartigem zellkarzinom mit rekombinantem, humanem alpha-interferon |
| US5256410A (en) * | 1988-12-01 | 1993-10-26 | Schering Corporation | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
| WO1992011025A2 (en) * | 1990-12-21 | 1992-07-09 | Schering Corporation | Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases |
| EP3600379B1 (de) | 2017-03-31 | 2022-12-21 | Accanis Biotech F&E GmbH & Co KG | Vorbeugung und behandlung von nichtmelanom-hautkrebs (nmsc) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0305551A3 (de) * | 1981-10-13 | 1990-01-10 | Exovir, Inc. | Pharmazeutische Zusammensetzungen zur topischen Anwendung |
| WO1983002460A1 (en) * | 1982-01-15 | 1983-07-21 | Cetus Corp | Interferon-alpha 74 |
| US5098703A (en) * | 1982-01-15 | 1992-03-24 | Cetus Corporation | Interferon-alpha 76 |
| AU1153083A (en) * | 1982-01-15 | 1983-07-28 | Cetus Corporation | Interferon-alpha 54 |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
-
1987
- 1987-05-25 ZA ZA873743A patent/ZA873743B/xx unknown
- 1987-05-25 PH PH35292A patent/PH26198A/en unknown
- 1987-05-25 IE IE135887A patent/IE62318B1/en not_active IP Right Cessation
- 1987-05-25 CA CA000537837A patent/CA1295243C/en not_active Expired - Fee Related
- 1987-05-25 AU AU73366/87A patent/AU601741B2/en not_active Ceased
- 1987-05-25 DK DK264787A patent/DK264787A/da not_active Application Discontinuation
- 1987-05-26 JP JP62129563A patent/JPS62289526A/ja active Pending
- 1987-05-26 DE DE87304642T patent/DE3788899T2/de not_active Expired - Fee Related
- 1987-05-26 ES ES87304642T patent/ES2061496T3/es not_active Expired - Lifetime
- 1987-05-26 KR KR870005198A patent/KR870010871A/ko not_active Application Discontinuation
- 1987-05-26 IL IL82654A patent/IL82654A0/xx not_active IP Right Cessation
- 1987-05-26 EP EP87304642A patent/EP0248583B1/de not_active Expired - Lifetime
- 1987-05-26 AT AT87304642T patent/ATE100717T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62289526A (ja) | 1987-12-16 |
| IL82654A0 (en) | 1987-11-30 |
| DK264787A (da) | 1987-11-28 |
| AU601741B2 (en) | 1990-09-20 |
| EP0248583A2 (de) | 1987-12-09 |
| ZA873743B (en) | 1987-11-25 |
| IE871358L (en) | 1987-11-27 |
| DE3788899D1 (de) | 1994-03-10 |
| IE62318B1 (en) | 1995-01-25 |
| CA1295243C (en) | 1992-02-04 |
| EP0248583A3 (en) | 1989-10-18 |
| ATE100717T1 (de) | 1994-02-15 |
| DE3788899T2 (de) | 1994-05-05 |
| EP0248583B1 (de) | 1994-01-26 |
| DK264787D0 (da) | 1987-05-25 |
| KR870010871A (ko) | 1987-12-18 |
| AU7336687A (en) | 1987-12-03 |
| ES2061496T3 (es) | 1994-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greenway et al. | Treatment of basal cell carcinoma with intralesional interferon | |
| US5028422A (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| DE69333321T3 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| Harms et al. | A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-γ in the local treatment of cutaneous leishmaniasis | |
| US5256410A (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
| US5002764A (en) | Treatment of actinic keratoses with alpha2 interferon | |
| CA1295243C (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| Jimenez et al. | Treatment with ImuVert/JV-Acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia | |
| US4806347A (en) | Interferon combinations | |
| Barr et al. | Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents | |
| AU636312B2 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| CA2004202C (en) | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon | |
| JP2784401B2 (ja) | 慢性骨髄性白血病の治療方法 | |
| DE60020442T2 (de) | Behandlung von Nierenzellen-Karzinom | |
| Rosso et al. | Antitumoral activity of human fibroblast interferon administered intranodularly | |
| Ohanian et al. | Analysis of the intralesional adriamycin-induced regression of primary and metastatic growth of line-10 guinea-pig hepatoma | |
| Shuttleworth et al. | A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease | |
| WO1990000406A1 (en) | Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon | |
| Tanigaki et al. | A case of squamous cell carcinoma treated by intralesional injection of oil bleomycin | |
| Maeda et al. | Combined antitumor effects of TNF and G-CSF on a human medulloblastoma xenograft line | |
| MALECI et al. | Pharmacokinetics of recombinant interferon-α2 following intralesional administration in malignant glioma patients | |
| DE60020635T2 (de) | Chronische myeloide Leukämie Therapie |